newsfilter
← Latest News
GlobeNewswire·

Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026

Presented first-in-human clinical imaging and dosimetry data for AKY-2519, supporting a broad clinical development program in patients with prostate, lung, and other B7-H3 expressing solid tumorsEnrolling patients in